|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
| An Ancillary Study of the STAMPEDE Trial Assessing the Clinical Qualification of Transcriptome Signatures for Advanced Prostate Cancer Starting ADT +/- Abiraterone Acetate and Prednisolone |
Gerhardt Attard, MD, Ph.D., FRCP
Gerhardt Attard joins Ashley Ross in discussing an ancillary study of the STAMPEDE trial assessing the clinical qualification of transcriptome signatures for advanced prostate cancer starting ADT with or without abiraterone acetate and prednisolone
|
|
|
|
|
|
|
|
|
|
|
| How Can Treatment Be Individualized By Using Genomic Classifiers? |
| Felix Y. Feng, MD |
| At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC) Hybrid Meeting, Felix Feng presents how treatment for prostate cancer can be individualized by using genomic classifiers. |
|
|
|
|
|
|
|
|
|
|
|
| Clinical Qualification of Transcriptome Signatures for Advanced Prostate Cancer Starting ADT with or Without Abiraterone Acetate and Prednisolone: An Ancillary Study of the STAMPEDE AAP Trial
|
| Marina Parry, BSc, Ph.D.
|
| Marina Parry discusses an ancillary study of the STAMPEDE trial assessing clinical qualification of transcriptome signatures for advanced prostate cancer starting ADT with or without abiraterone acetate and prednisolone. The addition of abiraterone acetate and prednisolone to ADT is standard of care for advanced prostate cancer (metastatic, M1 and high-risk non-metastatic, M0).
|
|
|
|
|
|
| Additional Insights from the STAMPEDE Trial Platform
|
| Elena Castro, MD |
| The 2022 ESMO annual meeting featured a prostate cancer session, including a discussant presentation by Elena Castro discussing two key studies from the STAMPEDE trial platform, including “Comparison of abiraterone acetate and prednisolone or combination enzalutamide + abiraterone acetate and prednisolone for mHSPC starting ADT: OS results of 2 randomized Phase III trials from the STAMPEDE protocol” presented by Gerhardt Attard, and “Clinical qualification of transcriptome signatures for advanced prostate cancer starting ADT with or without abiraterone acetate and prednisolone: an ancillary study of the STAMPEDE AAP trial” presented by Marina Parry.
|
|
|
|
|
|
|
|
|
|
|
| How Can Treatment Be Individualized By Using Genomic Classifiers? |
| Felix Feng, MD |
| Felix Feng discusses how treatment can be individualized by using genomic classifiers. Dr. Feng starts by highlighting that genomic biomarkers are included in certain treatment guidelines for the management of PSA recurrences. In the NCCN guidelines, the Decipher molecular assay is recommended for risk stratification among men with PSA persistence or recurrence. Additional evidence needs to be generated to support other potential treatment decisions in the PSA recurrent setting. |
|
|
|
|
|
| Comparison of Abiraterone Acetate and Prednisolone or Combination Enzalutamide + Abiraterone Acetate and Prednisolone for mHSPC Starting ADT: OS Results of 2 Randomized Phase III Trials from the STAMPEDE Protocol |
| Gerhardt Attard, MD, PhD |
| Gerhardt Attard discusses a comparison of abiraterone acetate and prednisolone or combination enzalutamide + abiraterone acetate and prednisolone for mHSPC starting ADT. Previous studies note that abiraterone acetate and prednisolone or enzalutamide added to ADT improves outcomes for mHSPC. Combining enzalutamide and abiraterone acetate and prednisolone may improve rPFS in mCRPC but no discernible improvement in OS and the benefit in mHSPC is uncertain. |
|
|
|
|
|
|
